1- ignore and don't engage in any way with the equity owners who control such a significant number of key customers (don't let the fact that all our competitors have equity ownership teams bother you)?
2 - ignore and don't engage in any way with the specialty prescription adjudicators (don't let the fact that all our competitors interface in various ways bother you)?
3- ignore that apremilast has a PSA indication. 100% just ignore it. Don't produce any promotional items that support it. (Don't let the fact that new topicals and deucravacitinib don't have a PSA indication bother you)? That's what happened when people in charge can only read data charts, but don't know what they mean. Don't know nuance. Don't know holistic dermatology.
4-ignore pediatrics indication entirely. That's what happens when you have people in charge who know zero about dermatology. Who cares in the data say less than 1% of the market is pediatric. The indication is NEW. The product is 10+years old and stale. Customers are starved for something new. Reps are starved for something new. Use it to grow the 99% of the market that is adult and looking for safety. Did upadacitinib make a big deal out of their pediatric data? Did the new topicals? Do you think they are growing peds or looking the grow the whole molecule?
Clown Show All Around. No wonder NBRX continues to tank.
2 - ignore and don't engage in any way with the specialty prescription adjudicators (don't let the fact that all our competitors interface in various ways bother you)?
3- ignore that apremilast has a PSA indication. 100% just ignore it. Don't produce any promotional items that support it. (Don't let the fact that new topicals and deucravacitinib don't have a PSA indication bother you)? That's what happened when people in charge can only read data charts, but don't know what they mean. Don't know nuance. Don't know holistic dermatology.
4-ignore pediatrics indication entirely. That's what happens when you have people in charge who know zero about dermatology. Who cares in the data say less than 1% of the market is pediatric. The indication is NEW. The product is 10+years old and stale. Customers are starved for something new. Reps are starved for something new. Use it to grow the 99% of the market that is adult and looking for safety. Did upadacitinib make a big deal out of their pediatric data? Did the new topicals? Do you think they are growing peds or looking the grow the whole molecule?
Clown Show All Around. No wonder NBRX continues to tank.